Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02704273 · ClinicalTrials.gov registry record
A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects
A clinical trial, sponsored by Astellas Gene Therapies.
- Completed
- Registry status
- 34
- Enrollment target
NCT02704273 is a clinical trial that has completed, run by Astellas Gene Therapies. The registered enrollment target is 34 participants.
The verdict
NCT02704273 has completed, sponsored by Astellas Gene Therapies.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM and for future evaluation of potential therapies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-07 |
| Est. Completion | 2019-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02704273
The ClinicalTrials.gov registry entry for NCT02704273 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Gene Therapies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02704273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02704273 about?
NCT02704273 is a clinical study titled "A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects". This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM an...
What is the current status of trial NCT02704273?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2016-07. Estimated completion is 2019-09.
Who is sponsoring clinical trial NCT02704273?
This trial is sponsored by Astellas Gene Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.